Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange
17 janv. 2023 16h05 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical...
The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System
05 déc. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall
18 oct. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
11 oct. 2022 06h45 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program
23 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
20 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange
16 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
07 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System
01 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
07 juil. 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...